Network-based microbial compositions and methods
Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.
1. A method of treating or reducing the severity of a disorder selected from the group consisting of Clostridium difficile infection and ulcerative colitis, comprising: administering to a mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, the therapeutic bacterial composition comprising a plurality of isolated bacteria, wherein the plurality of isolated bacteria comprises: a first bacterial operational taxonomic units (OTU) comprising a 16S rDNA comprising a sequence at least 97% identical to SEQ ID NO: 774, a second bacterial OTU comprising a 16S rDNA comprising a sequence at least 97% identical to SEQ ID NO: 856, a third bacterial OTU comprising a 16S rDNA comprising a sequence at least 97% identical to SEQ ID NO: 880, and a fourth bacterial OTU comprising a 16S rDNA comprising a sequence at least 97% identical to SEQ ID NO: 1670.
2. The method of claim 1 , wherein the first bacterial OTU comprises a 16S rDNA comprising SEQ ID NO: 774, the second bacterial OTU comprises a 16S rDNA comprising SEQ ID NO: 856, the third bacterial OTU comprises a 16S rDNA comprising SEQ ID NO: 880, and the fourth bacterial OTU comprises a 16S rDNA comprising SEQ ID NO: 1670.
3. The method of claim 1 , wherein the therapeutic bacterial composition is substantially depleted of a residual habitat product of a fecal material.
4. The method of claim 1 , wherein the therapeutic bacterial composition is capable of inducing the formation of IgA, RegIII-gamma, IL-10, regulatory T cells, TGF-beta, alpha-defensin, or beta-defensin in the mammalian subject.
5. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form including at least one pharmaceutically acceptable carrier.
6. The method of claim 5 , wherein the oral finished pharmaceutical dosage form comprises at least about 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition.
7. The method of claim 5 , wherein the oral finished pharmaceutical dosage form is a capsule.
8. The method of claim 5 , wherein the oral finished pharmaceutical dosage form is a tablet.
9. The method of claim 5 , wherein the oral finished pharmaceutical dosage form is a powder.
10. The method of claim 1 , wherein the therapeutic bacterial composition is prepared by ethanol treatment.
11. The method of claim 1 , wherein the therapeutic bacterial composition is prepared by heat treatment.
12. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form comprising at least 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition and including at least one pharmaceutically acceptable carrier and the therapeutic bacterial composition is prepared by ethanol treatment.
13. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form comprising at least 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition and including at least one pharmaceutically acceptable carrier and the therapeutic bacterial composition is prepared by heat treatment.
14. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form comprising at least 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition and including at least one pharmaceutically acceptable carrier and the therapeutic bacterial composition is prepared by ethanol treatment, and wherein the therapeutic bacterial composition is substantially depleted of a residual habitat product of a fecal material.
15. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form comprising at least 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition and including at least one pharmaceutically acceptable carrier and the therapeutic bacterial composition is prepared by heat treatment, and wherein the therapeutic bacterial composition is substantially depleted of a residual habitat product of a fecal material.
16. The method of claim 1 , wherein the therapeutic bacterial composition is provided as an oral finished pharmaceutical dosage form comprising at least 1×10 4 colony forming units of each of the first, second, third, and fourth bacterial OTUs per dose of the composition and including at least one pharmaceutically acceptable carrier and wherein the oral finished pharmaceutical dosage form is a capsule, a tablet, or a powder.
17. The method of claim 1 , comprising administering an antibiotic to the mammalian subject prior to administering the therapeutic bacterial composition.